JP2024535132A - 多発性骨髄腫を治療する方法 - Google Patents

多発性骨髄腫を治療する方法 Download PDF

Info

Publication number
JP2024535132A
JP2024535132A JP2024540838A JP2024540838A JP2024535132A JP 2024535132 A JP2024535132 A JP 2024535132A JP 2024540838 A JP2024540838 A JP 2024540838A JP 2024540838 A JP2024540838 A JP 2024540838A JP 2024535132 A JP2024535132 A JP 2024535132A
Authority
JP
Japan
Prior art keywords
antibody
dose
administered
daratumumab
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535132A5 (https=
Inventor
マイケル スペクター
スーザン ビー． ソボロフ－ジェインズ
Original Assignee
カエルム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カエルム バイオサイエンシズ インコーポレイテッド filed Critical カエルム バイオサイエンシズ インコーポレイテッド
Publication of JP2024535132A publication Critical patent/JP2024535132A/ja
Publication of JP2024535132A5 publication Critical patent/JP2024535132A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024540838A 2021-09-14 2022-09-08 多発性骨髄腫を治療する方法 Pending JP2024535132A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163244113P 2021-09-14 2021-09-14
US63/244,113 2021-09-14
US202163285435P 2021-12-02 2021-12-02
US63/285,435 2021-12-02
US202263400882P 2022-08-25 2022-08-25
US63/400,882 2022-08-25
PCT/US2022/042944 WO2023043658A2 (en) 2021-09-14 2022-09-08 Method of treating multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024535132A true JP2024535132A (ja) 2024-09-26
JP2024535132A5 JP2024535132A5 (https=) 2025-08-25

Family

ID=85603424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540838A Pending JP2024535132A (ja) 2021-09-14 2022-09-08 多発性骨髄腫を治療する方法

Country Status (8)

Country Link
US (1) US20240392028A1 (https=)
EP (1) EP4401839A4 (https=)
JP (1) JP2024535132A (https=)
KR (1) KR20240055101A (https=)
AU (1) AU2022346750A1 (https=)
CA (1) CA3231073A1 (https=)
MX (1) MX2024003215A (https=)
WO (1) WO2023043658A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025194030A1 (en) * 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
CR20190291A (es) * 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
US20190298827A1 (en) * 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
CN115298214A (zh) * 2019-11-15 2022-11-04 田纳西大学研究基金会 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白
CA3192069A1 (en) * 2020-09-14 2022-03-17 Michael Spector Method of treating amyloidosis

Also Published As

Publication number Publication date
US20240392028A1 (en) 2024-11-28
EP4401839A4 (en) 2025-08-06
CA3231073A1 (en) 2023-03-23
WO2023043658A2 (en) 2023-03-23
EP4401839A2 (en) 2024-07-24
MX2024003215A (es) 2024-07-19
KR20240055101A (ko) 2024-04-26
AU2022346750A1 (en) 2024-04-11
WO2023043658A3 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
JP7389077B2 (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2022546454A (ja) がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
US20200268847A1 (en) Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone
US20230364228A1 (en) Method of treating amyloidosis
JP2012526846A (ja) ループス治療のための方法および組成物
CA3110276A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
TW202011954A (zh) 第三期nsclc之治療及與該治療相關之病理症狀之減緩
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
CN118043072A (zh) 治疗多发性骨髓瘤的方法
WO2019229155A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
JP2024535132A (ja) 多発性骨髄腫を治療する方法
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
US20220031840A1 (en) Method of Treatment
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体
EA050760B1 (ru) Способ лечения множественной миеломы
EA053286B1 (ru) Способ лечения амилоидоза
CN116782935A (zh) 治疗淀粉样变性的方法
IL293615A (en) Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
JP2025515344A (ja) 抗ｐｄ－１抗体と抗ｅｇｆｒ抗体との組み合わせ及び頭頸部扁平上皮がんの治療におけるその使用
HK40110052A (zh) 用於治疗癌症的方法和组合物
CN121843712A (zh) 用于治疗多发性硬化症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250815